Acceptability of Artificial Intelligence in the Diagnosis of Prostate Cancer

This study investigates the acceptability of artificial intelligence (AI) as a diagnostic support tool among patients with localized prostate cancer and healthcare providers, as well as their willingness to share health data for AI development. Background AI tools in healthcare show promising potential, especially in improving diagnosis accuracy and personalizing treatment. However, successful implementation depends not only on technical performance but also on the acceptability of AI among its users-both patients and professionals. Prior research has shown varied acceptability depending on context, disease severity, task performed by AI, and user population. Objectives Assess patients' acceptability of AI as a diagnostic support in prostate cancer. Explore patients' willingness to share health data for developing clinical AI. Assess healthcare providers' acceptability of AI in this diagnostic context. Methodology Design: A cross-sectional, mixed-method, multinational study (Belgium, Italy, Spain). Quantitative Phase: Online questionnaire, using adapted theoretical frameworks (Value Perception Model, NASSS-AI, TFA). Qualitative Phase: Will follow based on quantitative findings. Participants: Adults diagnosed with localized prostate cancer. Recruitment via hospitals, social media, and patient associations. Data Collected: Personal and health information, attitudes toward AI, willingness to share data. Ethics Approved by ethics committees in each participating country. Informed consent obtained digitally before participation. Data anonymized and GDPR-compliant.

NCT Number	NCT07074405
Lead Sponsor	Centre Hospitalier Universitaire de Liege
Conditions	Prostate Cancer
Enrollment	51 participants
Start Date	2024-12-02
Primary Completion	2025-12-31 (estimated)
Study Completion	2025-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-03-27